Apidra SoloStar (insulin glulisine) NDC 0088-2502

NDC codes

FDA NDC Directory

Product NDC (as listed)0088-2502Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00088-2502Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0088-2502-01	00088250201	1 SYRINGE, PLASTIC in 1 CARTON (0088-2502-01) / 3 mL in 1 SYRINGE, PLASTICMarketed from Feb 24, 2009
0088-2502-05	00088250205	5 SYRINGE, PLASTIC in 1 CARTON (0088-2502-05) / 3 mL in 1 SYRINGE, PLASTIC (0088-2502-00)Marketed from Feb 24, 2009

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Apidra SoloStar
Generic name (nonproprietary): insulin glulisine
Active ingredients: Insulin glulisine — 100 [iU]/mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: sanofi-aventis U.S. LLC
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 021629
Marketing start: Feb 24, 2009
Listing expires: Dec 31, 2026
Other FDA classes: Insulin (Chemical/Ingredient)
Identifiers: Product ID 0088-2502_6be54063-6912-4810-b1c7-dfca969224d8SPL ID 6be54063-6912-4810-b1c7-dfca969224d8SPL set ID e7af6a7a-8046-4fb4-9979-4ec4230b23aaRxCUI 485210, 803194, 847259, 847261UNII 7XIY785AZD
Pharmacologic class: Insulin Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N400088250201 followed by a unit qualifier and the quantity

Package 00088-2502-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 25, 2025.

Indications (excerpt from the label)

APIDRA is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. APIDRA is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 021629

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 021629
Product	Strength	Form · route	Labeler	Product NDC
Apidrainsulin glulisine	Insulin glulisine 100 [iU]/mL	Injection, SolutionIntravenous, Subcutaneous	sanofi-aventis U.S. LLC	0088-2500